This pattern appears to be a recurrent theme in molecular drug responses: for example, very recently it was reported that CYP17A1 level was markedly increased in tumor biopsies from CRPC patients after CYP17A1 inhibitor therapy [40]. This evidence concerns the gene CYP17A1 and neoplasm.